Group 1 - The report by CICC International Consulting highlights the extensive database and analytical capabilities of the company, which includes approximately 8 billion data resources across various sectors, ensuring authoritative and credible data support [2][24] - CICC has developed independent analytical models and consulting frameworks, collaborating with government, academia, and business sectors to enhance the quality and compliance of its consulting outcomes [2][24] Group 2 - Respiratory Syncytial Virus (RSV) is a highly contagious virus primarily affecting children under 5 and the elderly, with a seasonal prevalence from October to May, peaking in December to February in temperate regions [3][4] - The global burden of RSV is significant, with an estimated 33 million cases of lower respiratory tract infections in children under 5 annually, leading to 3.6 million hospitalizations and 118,000 deaths [4] Group 3 - The market for passive immunization agents against RSV in infants aged 0-1 in China is projected to grow at a compound annual growth rate (CAGR) of 78.40%, reaching a market size of 2.99 billion yuan from 2024 to 2028 [5][6] - The demand for RSV prevention products is expected to increase due to rising awareness and the introduction of various monoclonal antibody options, indicating a growing market potential [5][6]

Core Viewpoint - The Respiratory Syncytial Virus (RSV) is the leading pathogen detected in hospitalized severe acute respiratory infection cases in China, indicating a persistent epidemic status and necessitating enhanced preventive measures [1][2]. Group 1: RSV Prevalence and Impact - RSV has consistently ranked among the top three pathogens in hospitalized severe acute respiratory infection cases from the 4th to the 27th week of 2025, maintaining a detection rate of around 10% [1][2]. - The virus poses a significant threat to infants, particularly those under one year old, as it is the primary cause of lower respiratory infections leading to hospitalization in this age group [1][2]. Group 2: Preventive Measures and Recommendations - Public health measures, including health education and immunization, should be integrated into medical services to reduce the risk of severe cases in infants [1]. - High-risk groups, such as premature infants and those with congenital conditions, are advised to receive the monoclonal antibody Nirsevimab, which is the first preventive measure for all infants against RSV [2]. Group 3: Monitoring and Data Utilization - Continuous monitoring of RSV through weekly reports is essential for understanding its prevalence and guiding preventive strategies [2]. - The protective effect of the monoclonal antibody lasts approximately 5-6 months, aligning with the RSV epidemic season, thus facilitating a connection between prevention and treatment [2].